Bio Key International INC 8-K filings

BIO-key International announced a 13% increase in Q2 revenues and a 51% reduction in net loss, driven by strong license fee growth and international contract wins.

BIO-key International has entered into a warrant exercise agreement, reducing the exercise price on existing warrants and issuing new warrants, contingent on shareholder approval.

BIO-key International, Inc. has appointed M&K CPAS, PLLC as its new independent registered public accounting firm, while dismissing Bush & Associates CPA LLC.

BIO-key International announced its common stock will resume trading on the Nasdaq Capital Market on July 8, 2026, after regaining compliance with listing standards.

BIO-key International has received a notice of non-compliance from Nasdaq due to the delayed filing of its Form 10-Q for the period ended March 31, 2026.

BIO-key International reports a 34% revenue increase in Q1 2026, with significant improvements in net loss, and anticipates profitability in Q2 2026 driven by a projected 65% revenue surge.

BIO-key International's common stock will be suspended from Nasdaq trading effective May 12, 2026, due to bid price and late filing issues, with trading to commence on OTC Markets the following day.

BIO-key International stockholders have authorized the Board of Directors to implement a reverse stock split at a ratio between 1-for-2 and 1-for-10.

BIO-key International received a Nasdaq non-compliance notice due to a delayed 2025 Annual Report filing.

BIO-key International anticipates a 50% surge in first-half 2026 revenues to approximately $5 million, projecting positive net income compared to a loss in the prior year.

BIO-key International, Inc. announced its 2025 financial results, reporting a revenue decline but a substantially improved cash position and strong preliminary Q1 2026 revenue growth, supporting expected growth in 2026.

BIO-key International, Inc. announced a $1.04 million license renewal and expansion with a foreign retail bank, alongside a strong year-end cash position.

BIO-key International, Inc. announced its third-quarter 2025 results, reporting a net loss of $964,849 on revenues of $1.55 million, while strengthening its balance sheet with a post-quarter $3.1 million capital raise.

BIO-key International, Inc. received an additional 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, pushing the deadline to May 4, 2026.

BIO-key International raised $3.1 million in gross proceeds from a warrant exercise and fully repaid a $2.36 million secured note through a debt-for-equity exchange.

BIO-KEY International, Inc. has secured a $1.13 million senior secured promissory note from Streeterville Capital, LLC, providing $1 million in net proceeds for working capital at a high effective cost and pledging substantially all company assets.

BIO-key International, Inc. stockholders approved amendments to increase shares available under its 2023 Stock Incentive Plan and 2021 Employee Stock Purchase Plan by 700,000 shares each.

BIO-key International, Inc. stockholders approved all five proposals, including director elections and compensation plans, at their Annual Meeting on August 8, 2025.

BIO-key International reports significant Q2 2025 revenue growth driven by increased sales across all three segments and launches a new CyberDefense Initiative.

BIO-key International reports a 25% year-over-year revenue decrease for Q1 2025, but highlights a strengthened cash position and strategic partnerships.

BIO-key International, Inc. (BKYI) has regained compliance with Nasdaq Listing Rule 5250(c)(1) after a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2024.

BIO-key International reduced its 2024 net loss by 49% to $4.3 million, driven by higher gross margins and lower operating costs, despite an 11% revenue decrease due to a strategic shift away from low-margin services.

BIO-key International, Inc. has entered into agreements to raise approximately $3.8 million through a warrant exercise and reduce debt by exchanging promissory notes for common stock.

BIO-key International has regained compliance with Nasdaq's minimum stockholders' equity requirement by acquiring shares of Boumarang Inc. in exchange for company stock.

BIO-key International has acquired 5 million shares of Boumarang, Inc. in exchange for 595,000 of its own shares, a move that is expected to strengthen its balance sheet by $5 million.

BIO-key International announced an 18% increase in revenue to $2.1 million for Q3 2024, alongside a reduced net loss and improved cash position.

BIO-key International has entered into a warrant exercise agreement with an existing investor, resulting in approximately $1.9 million in gross proceeds.

BIO-key International held its annual meeting on August 22, 2024, where stockholders elected directors, ratified the auditor, and approved executive compensation matters.

BIO-key International reported a reduced net loss and improved cash flow from operations in Q2 2024, despite a decrease in revenue due to delayed software license recognition and lower project-related services revenue.

BIO-key International has entered into a note purchase agreement, securing $2 million in net proceeds for general working capital through a senior secured promissory note.